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Morphological changeHistidine-rich glycoprotein (HRG) is a plasma protein implicated in the innate immune system. In recent
studies, we showed that either HRG, or the Arg23-Lys66 glycopeptide derived from HRG, in concert with
concanavalin A (Con A), promotes a morphological change and adhesion of the human leukemic T-cell line
MOLT-4 to culture dishes, and that cell surface glycosaminoglycan or Fcγ receptors do not participate in this
cellular event. In the present study, we identiﬁed the α-subunit of ATP synthase as one of the HRG-binding
proteins on the surface of T-cells by HRG-derived glycopeptide afﬁnity chromatography and by a peptide
mass ﬁnger printing method. HRG speciﬁcally interacted with mitochondrial ATP synthase with a
dissociation constant of 66 nM. The presence of α- and β-subunits of ATP synthase on the plasma
membrane of MOLT-4 cell was demonstrated by immunoﬂuorescent staining and FACS analysis. The HRG/
Con A-induced morphological changes of MOLT-4 cells were speciﬁcally inhibited by a monoclonal antibody
against the β-subunit of ATP synthase. These results strongly suggest that the cell surface ATP synthase
functions as a binding protein for HRG on MOLT-4 cells, which is required for the morphological changes
observed in MOLT-4 cells following treatment with HRG/Con A.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Human histidine-rich glycoprotein (HRG) is a single chain
glycoprotein with a molecular mass of 67 kDa that is synthesized in
the liver and present in plasma at a rather high concentration (115 μg/
ml, 1.7 μM) [1]. HRG belongs to the cystatin superfamily that includes
fetuins and kininogens, consisting of six domains that include
cystatin-like domains 1 and 2, proline-rich domain 1, histidine-rich
domain, proline-rich domain 2 and C-terminal domain [2,3].
HRG has been reported to interact with various ligands in vitro
and suggested to play a role as a modulator not only in blood
coagulation and ﬁbrinolysis but also in the innate immune systems
[4]. In the immune systems, HRG was ﬁrst recognized as an
autorosette inhibitor between murine lymphocytes and erythrocytes
[5,6]. HRG binds to T-cells and inhibits proliferation of peripheral T-
lymphocytes induced by anti-CD3 antibody [7]. HRG also binds toacid; Con A, concanavalin A;
S, Fetal bovine serum; HRG,
; TPCK, N-tosyl-L-phenylalanyl
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ll rights reserved.Fcγ receptor on phagocytic leukocytes, modulates the expression of
macrophage Fcγ receptor and the associated phagocytic function by
its N-terminal domain [8], and regulates phagocytosis of apoptotic
and necrotic cells by leukocytes [8–10]. Recent reports suggest that
the histidine-rich domain of HRG has anti-angiogenic [11], anti-
tumor [12] and anti-bacterial activities [13] similar to the domain 5
of high molecular weight kininogen [14–16]. However, patients with
a congenital deﬁciency of HRG failed to exhibit any hemostatic
abnormalities [17] and HRG-knockout mice were shown to be viable
and fertile [18]. Therefore, the physiological role of HRG still remains
enigmatic.
Other than leukocytes, HRG has been shown to interact with a
wide range of cells such as activated platelets [19], and endothelial,
melanoma, ﬁbroblast and tumor cell lines [20]. However, a cell surface
receptor for HRG has not been ﬁrmly determined. HRG binds to
heparan sulfate proteoglycans and tropomyosin on endothelial cells
[21,22]. Presence of a receptor protein with 56 kDa on the cell surface
has been shown using 125I surface-labeled T-lymphocytes [7], but the
putative protein was not puriﬁed or characterized.
HRG has been shown to potentiate the morphological changes in
the human T-cell line MOLT-3 following treatment with concanavalin
A (Con A), which results in their adhesion to culture dishes [23]. Our
previous study indicated that HRG and Con A also promoted
morphological changes of the human T-cell line MOLT-4 cells similar
to MOLT-3 cells, and synergistically stimulated a phosphatidylinositol
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In addition, we explored the functional site of human HRG and
identiﬁed a glycopeptide composed of Arg23 to Lys66 containing a
carbohydrate at Asn45 as an active fragment. The Arg23-Lys66
glycopeptide induced a comparable shape change-promoting activity
to intact HRG that was insensitive to exogenous heparin. While the
Fcγ receptor was reported to be a cell surface receptor for HRG in
phagocytic leukocytes [8], MOLT-4 cells do not express the cell surface
Fcγ receptor. Therefore, the presence of a speciﬁc receptor for HRG on
MOLT-4 cell membrane, distinct from cell surface glycosaminoglycan
or Fcγ receptor, was strongly suggested.
In this study, theHRG-bindingproteinonMOLT-4 cellmembranewas
isolatedﬁrst by using theArg23-Lys66 glycopeptide as an afﬁnity ligand.
The α-subunit of F1FO-ATP synthase was tentatively identiﬁed as a
surfacebindingprotein forHRG, and thedistribution of theATP synthase
subunits was examined on the cell surface. Subsequently, speciﬁc
interaction between HRG and the bovine heart mitochondrial ATP
synthasewas characterizedusing an InteractionAnalysis system (IAsys).
Finally, the effects of antibodies for ATP synthase α- and β-subunits on
the morphological change-promoting activity of HRG were analyzed to
examine whether ATP synthase could be involved in this cellular event.
2. Materials and methods
2.1. Proteins and materials
Human HRG and antithrombin were isolated from human plasma
according to a published procedure [24]. The Arg23-Lys66 glycopeptide
(Arg23-Arg-Arg-Asp-Gly-Tyr-Leu-Phe-Gln-Leu-Leu-Arg-Ile-Ala-Asp-
Ala-His-Leu-Asp-Arg-Val-Glu-Asn⁎-Thr-Thr-Val-Tyr-Tyr-Leu-Val-Leu-
Asp-Val-Gln-Glu-Ser-Asp-Cys-Ser-Val-Leu-Ser-Arg-Lys66 where a car-
bohydrate is attached at Asn⁎) was isolated as follows. HRG was ﬁrst
reduced and S-pyridylethylated, and digestedwith lysylendopeptidase.
The peptide was separated from the digest by a reversed-phase HPLC.
Thepurityand the amountof thepeptidewere assessedbyaMALDI-TOF
mass spectrometer and an amino acid analyzer. Bovine mitochondrial
F1FO-ATP synthase was kindly provided by Prof. S. Yoshikawa (Uni-
versity of Hyogo, Hyogo, Japan). Aprotinin was obtained from TAKARA
BIO Inc. (Shiga, Japan). BSA, carbonic anhydrase, Con A, bovine fetuin-A,
ovalbumin, N-tosyl-L-phenylalanyl chloromethyl ketone (TPCK)-trea-
ted trypsin, antibiotic antimycotic solution, α-cyano-4-hydroxycin-
namic acid (CHCA) and RPMI 1640 media (R8758) were obtained from
Sigma-Aldrich Co. (St. Louis, MO). Fetal bovine serum (FBS) was
obtained from Biological Industries (Israel). Leupeptin was obtained
from PEPTIDE INSTITUTE, Inc. (Osaka, Japan). Mouse monoclonal
antibodies raised against α- and β-subunits of ATP synthase were
obtained fromMolecular Probes (Eugene, OR). Afﬁnity puriﬁed mouse
IgG1andIgG2b isotypecontrols andphycoerythrin (PE)-labeleddonkey
F(ab′)2 fragment anti-mouse IgG(H+L) were obtained from
eBioscience (San Diego, CA). Goat anti-mouse IgG antibody conjugated
to indocarbocyanine (Cy3) was obtained from Chemicon International
Inc. (Temecula, CA). VECTASTAIN ABC KIT was obtained from Vector
Laboratories, Inc. (Burlingame, CA). N-hydroxysuccinimide (NHS)-
activated Celluloﬁne was provided by Chisso Corporation (Tokyo,
Japan). NHS-activated Sepharose 4 Fast Flow was obtained from
Amersham Biosciences Co. (Tokyo, Japan). Silver stain reagent was
obtained from Daiichi Pure Chemical Co. Ltd. (Tokyo, Japan). PMSF was
obtained from Wako Pure Chemical Industries Ltd. (Osaka, Japan).
Sulfo-succinimidyl-6-(biotinamide) hexanoate (Sulfo-NHS-LC-Biotin),
Bis(sulfosuccinimidyl) suberate (BS3) for immobilization of ligand
proteins to IAsys aminosilane cuvettes and SuperSignal WestFemto
Maximum Sensitivity Substrate were obtained from Pierce Biotechnol-
ogy Inc. (Rockford, IL). Acetonitrile was obtained from Kanto Chemical
Co. (Tokyo, Japan). Other reagents and chemicals were obtained from
Nacalai Tesque (Kyoto, Japan) or Wako Pure Chemical Industries Ltd.
(Osaka, Japan).2.2. Cell culture
The leukemic T-cell line MOLT-4 was obtained from RIKEN
BioResource Center Cell Bank (Tsukuba, Japan) and maintained in
RPMI-1640 media supplemented with 10% heat-inactivated FBS and
0.2% antibiotic antimycotic solution in 10-cm culture dish at 37 °C
under 5% CO2. For large scale culture, MOLT-4 cells were cultured in
500-ml spinner ﬂasks.
2.3. Surface biotinylation of MOLT-4 cells
Conﬂuent MOLT-4 cells were collected, washed 3 times with
phosphate buffered saline (PBS), and suspended at a density of 2×107
cells/ml in PBS containing 1 mg/ml Sulfo-NHS-LC-Biotin. After
incubation for 1 h at 4 °C, the cells were collected, washed 3 times
with PBS and stored at −20 °C until use [15].
2.4. Preparation of afﬁnity gels
In order to isolate Arg23-Lys66 glycopeptide-binding proteins
from the extracts of MOLT-4 cells, the Arg23-Lys66 glycopeptide was
covalently coupled to NHS-activated Celluloﬁne or NHS-activated
Sepharose according to the manufacturer's instructions. The amount
of the peptide immobilized to gel was determined by quantiﬁcation of
the unbound peptide using an L-8500 Amino Acid Analyzer (HITACHI,
Tokyo, Japan) after acid hydrolysis. Approximately 5 nmol of Arg23-
Lys66 were immobilized to 100 μl of the Celluloﬁne, and 10 nmol to
200 μl Sepharose. We also prepared Tris-immobilized Sepharose as a
control gel.
2.5. Membrane preparation and solubilization
Cultured MOLT-4 cells were harvested, washed with PBS and
resuspended in PBS containing 1 mM EDTA, 0.5 μg/ml aprotinin,
0.5 μg/ml leupeptin, 0.5 mM PMSF (PBSi). Cells were disrupted by
three cycles of freeze-thawing using liquid N2 and a 37 °C water
bath. After centrifugation at 21,500 ×g for 20 min at 4 °C, the
pellet was suspended in PBSi. The protein concentration of the
membrane fraction was then quantiﬁed by a method using Quick
Start Bradford Protein Assay solution (Bio-Rad Laboratories, Inc.,
Hercules, CA). Solubilization of the membrane fraction at 1 mg/ml
protein concentration was performed for 1 h at 4 °C in PBSi
containing 2% Triton X-100, and the detergent-solubilized mem-
brane fraction was collected by centrifugation at 100,000 ×g for
1 h at 4 °C.
2.6. Isolation of Arg23-Lys66 binding proteins from MOLT-4 cells
Extracts from the membrane fraction of MOLT-4 cells were ﬁrst
applied to an Arg23-Lys66 Celluloﬁne column at 4 °C. After washing
with PBS containing 1% Triton X-100, bound proteins were eluted from
the column stepwisely with 10 mM sodium phosphate, 1% Triton X-
100, pH 7.0 containing either 0.5 M NaCl, 1 M NaCl or 2 M NaCl, and
ﬁnally with 20 mM Gly–HCl, pH 2.5 containing 150 mM NaCl and 1%
Triton X-100. The ﬁnal eluate was quickly restored to pH 7.0 by adding
one tenth volume of 1 M Tris–HCl buffer, pH 8.0. Isolation of binding
proteins using Tris-Sepharose and Arg23-Lys66-Sepharose columns
were also performed in the same manner. The Tris-Sepharose column
was used as a pre-column to remove non-speciﬁc binding proteins to
the Arg23-Lys66-Sepharose column.
2.7. Gel electrophoresis
The fractionated proteins were precipitated with an equal volume
of 20% trichloroacetic acid for 15 min on ice, pelleted at 21,500 ×g for
5 min at 4 °C, washed with 80% ice-cold acetone, and dried for 10 min
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proteins were then separated by SDS-PAGE on 12% (w/v) polyacry-
lamide gels and visualized by the silver staining kit.
2.8. In-gel digestion for protein identiﬁcation
In-gel digestion was performed according to the methods
described [25]. Brieﬂy, the excised gel band was destained with
15mMpotassium ferricyanide and 50mM sodium thiosulfate, and the
gel pieces were dehydrated with 25 mM NH4HCO3 and 50%
acetonitrile. After drying, the proteins in the gels were reduced and
S-carboxyamidomethylated, and then digested with TPCK-trypsin
(100 ng in 10 μl) on ice for 30 min, followed by the digestion at 37 °C
for 12–15 h. Peptides were extracted with 50% acetonitrile and 0.5%
triﬂuoroacetic acid, and dried.
2.9. MALDI-TOF mass spectrometry and database search
Extracted peptides were dissolved in 0.5% triﬂuoroacetic acid,
desalted, concentrated using an Eppendorf PerfectPure C-18 Tip
(Eppendorf, Hamburg, Germany), and spotted onto a MALDI sample
plate together with 5 mg/ml CHCA in 50% acetonitrile and 0.1%
triﬂuoroacetic acid. Peptide mass spectra were obtained using a
Voyager-DE Pro MALDI-TOF mass spectrometer (MALDI-TOF/MS,
Applied Biosystems, Foster City, CA) in a linear mode. External
calibrationwas carried out using a Sequazyme peptidemass standards
kit (PE Biosystems, Foster City, CA). Identiﬁcation of proteins was
performed by searching the NCBInr protein database using Profound
(http://prowl.rockefeller.edu/).
2.10. Western blot analysis and detection of biotinylated proteins
Proteins were resolved by SDS-PAGE and electrotransferred onto
PVDF membrane (Millipore Immobilon-P, Bedford, MA) by the
semidry technique. For western blot analysis, membranes were
blocked with 50 mM Tris–HCl, 150 mM NaCl, pH 8.0 (TBS) containing
5% (w/v) skim milk for 2 h at room temperature, and the α- or β-
subunit of ATP synthase was detected using themouse anti-α- or anti-
β-subunit of bovine ATP synthase antibody (0.2 μg/ml). To detect the
biotinylated proteins, the membranewas blocked with TBS containing
3% BSA and 0.02% Tween 20 overnight at 4 °C, incubated with a
streptavidin and biotinyl-horseradish peroxidase using VECTASTAIN
ABC KIT, and visualized by chemiluminescence using SuperSignal
WestFemto Maximum Sensitivity Substrate. The density of chemilu-
minescence was recorded by an Atto LightCapture AE-6955 (ATTO
Corporation, Tokyo, Japan). As a positive control, bovine mitochon-
drial F1FO-ATP synthase was also analyzed.
2.11. Detection of ATP synthase on cell surface
MOLT-4 cells were collected in a micro tube, washed with PBS,
ﬁxed in PBS containing 3.6% paraformaldehyde for 20 min at room
temperature, and washed with PBS again to remove free paraformal-
dehyde. The ﬁxed cells were mounted on glass coverslips coated with
poly-D-Lysine. Permeabilized cells were prepared by incubation of the
cell-ﬁxed coverslips with 0.02% TritonX-100 in PBS for 20 min at room
temperature. Unpermeabilized or permeabilized cells were then
incubated with the mouse monoclonal antibody raised against the
α- or β-subunit of mitochondrial ATP synthase (each 2 μg/ml) in PBS
containing 1% BSA for 30 min at room temperature. The cells were
thenwashed 3 times with PBS to remove excess primary antibody and
incubated for 30 min in the dark with a goat anti-mouse IgG antibody
conjugated to Cy3 (2 μg/ml) in PBS containing 1% BSA. After washing
with PBS to remove excess secondary antibody, images were obtained
using an OLYMPUS BX60 ﬂuorescence microscope (Olympus Optical
Co., Tokyo, Japan).2.12. FACS analysis
MOLT-4 cells were collected, washed 3 times with PBS and
suspended in 100 μl of PBS containing 0.1% BSA at a density of 1×106
cells/ml. After incubation at 4 °C for 1 h with the mouse monoclonal
antibody raisedagainst theα- orβ-subunitof bovinemitochondrialATP
synthase (each20 μg/ml)or isotype control antibody, IgG2bor IgG1, the
cells were collected, washed 3 times with PBS containing 0.1% BSA and
re-incubated with phycoerythrin-labeled secondary antibody for 1 h.
Then, cells were collected, washed, suspended in FACS buffer (PBS
containing 5% FBS), and analyzed by a FACS Calibur using the Cell Quest
Pro software (Becton Dickinson, Franklin Lakes, NJ). To conﬁrm the
interaction between HRG and ATP synthase on cell surface, cells were
ﬁrst incubatedwith orwithout 10 μg/ml HRG in 0.1% BSA at 4 °C for 1 h.
After washing the cells with 0.1% BSA in PBS, the binding of the anti-β-
subunit antibody was assayed as above.
2.13. Determination of binding speciﬁcity and dissociation constant using
an IAsys resonant mirror biosensor
Binding speciﬁcity and kinetic parameters were determined by a
resonantmirrordetectormethodusingan IAsys single channel resonant
mirror biosensor (Afﬁnity Sensors, Cambridge, U.K.) [26]. HRG was
covalently bound to an activated aminosilane cuvette according to the
manufacturer's instructions. To determine binding speciﬁcity, interac-
tion of mitochondrial F1FO-ATP synthase and several plasma proteins
including BSA, antithrombin and fetuin-Awith immobilized HRG were
monitored in TBS containing 0.5% Triton X-100 at 25 °C. Since BSA did
not show any interaction with immobilized HRG, subsequent experi-
ments were performed in the presence of 0.1% BSA. To determine the
dissociation constant between F1FO-ATP synthase and immobilized
HRG, F1FO-ATP synthase was serially diluted (2n; starting from 82.1 to
0.64 nM at a ﬁnal concentration in the cuvette) in TBS containing 0.5%
TritonX-100 and0.1%BSA. Each sample (5 μl)was added to 100 μl of TBS
containing 0.5% Triton X-100 and 0.1% BSAwithwhich the baselinewas
set for 3min, and bindingwasmonitored for 5min. The sensing surface
in a cuvette was then regenerated by incubating a cuvette with 20 mM
Gly–HCl,150mMNaCl, 0.5% TritonX-100, pH2.5, for 2min. The binding
parameters were calculated from the association and dissociation
phases of the binding reaction using the non-linear curve ﬁtting Fast Fit
software provided by themanufacturer. To conﬁrm the speciﬁc binding
between the immobilized Arg23-Lys66 glycopeptide and F1FO-ATP
synthase, HRG or the Arg23-Lys66 glycopeptide was added to the cu-
vette, and the binding of F1FO-ATP synthase (33 nM) was monitored.
2.14. Observation of morphological changes
Morphological changes induced by Con A and HRG treatment were
assessedas describedpreviously (Ohta et al., inpreparation). To analyze
the effects of antibodies on the cellularmorphological changes,MOLT-4
cells were suspended at a density of 1×105 cells/ml in 500 μl of serum-
freeRPMI1640mediaandﬁrst incubatedwith themonoclonal antibody
speciﬁc for theα- or β-subunit ofmitochondrial ATP synthase for 1 h at
37 °C. Then Con A (400 nM) and HRG (30 nM) were added and the
number of adhered cells was counted under a lightmicroscope after 6 h
at 37 °C. The effect of isotype control antibody IgG2b or IgG1 was also
examined in the same manner.
3. Results
3.1. The Arg23-Lys66 glycopeptide-binding protein is a 55 kDa protein on
the surface of MOLT-4 cells
We have previously demonstrated that the Arg23-Lys66 glycopep-
tide from human HRG, as well as native HRG, in concert with Con A,
promotes distinctmorphological changes ofMOLT-4 cells (Ohta et al., in
Fig. 1. Identiﬁcation of an Arg23-Lys66 glycopeptide-binding protein. The 2% Triton X-100 extracts derived from the membrane fractions of untreated MOLT-4 cells (A) and surface-
biotinylated MOLT-4 cells (B) were applied to the Arg23-Lys66 Celluloﬁne column. Binding proteins were eluted stepwisely with 0.5 M NaCl (lane 1), 1 M NaCl (lane 2), 2 M NaCl
(lane 3) and pH 2.5(lane 4) solutions. Each eluatewas separated by SDS-PAGE and visualized by silver staining (A). Cell surface proteins were detected as a biotin-labeled horseradish
peroxidase-streptavidin complex, after separation by SDS-PAGE and blotting onto PVDFmembrane (B). Molecular massmarkers (Mr) are indicated on the left side. The protein bands
I to VI in the polyacrylamide gel were excised, digested in-gel with trypsin and analyzed by MALDI-TOF/MS. (C) Mass spectrometric peptide map was used to identify the protein
using Profound program. The peptides whose observed mass values were ﬁtted with those of theoretical tryptic peptides of the α-subunit of human ATP synthase are indicated by
asterisk (⁎) and listed in Table 1. The “T” signs represent the autodigested fragments of trypsin. (D) Those peptides assigned to the amino acid sequence of the α-subunit of ATP
synthase are underlined. The membrane extracts of MOLT-4 cells were applied to the tandemly connected Tris- (lane 1) and Arg23-Lys66-immobilized (lane 2) Sepharose columns
and binding proteins to each column were separately eluted with pH 2.5 solution. The eluates were separated by SDS-PAGE and visualized by silver staining (E) or western blotting
with antibody against α-subunit (F) or β-subunit (G) of ATP synthase. As a positive control, mitochondrial ATP synthase was also run on lane 3 (E, F, G).
Table 1
List of the peptides derived from the 55 kDa protein by tryptic digestion and ﬁtted with
the α-subunit of ATP synthase.
Observed
mass
(M+H)
Calculated
mass
Error
(%)
Residues Peptide sequence
Start To
724.152 722.886 0.036 176 182 APGIIPR
816.166 814.940 0.027 162 169 GPIGSKTR
816.166 815.925 −0.094 127 133 EGDIVKR
816.166 814.937 0.027 208 214 ELIIGDR
893.203 892.023 0.019 435 441 LELAQYR
1021.102 1020.175 −0.008 262 270 RLTDADAMK
1180.500 1178.443 0.089 176 186 APGIIPRISVR
1554.657 1553.694 −0.003 335 347 EAYPGDVFYLHSR
3213.564 3212.567 0.000 435 463 LELAQYREVAAFAQFGSDLDAATQQLLSR
The observed mass was obtained from the tryptic digest of 55 kDa protein band using
MALDI-TOF mass spectrometer, and the calculated mass was obtained theoretically
from the amino acid sequence of the α-subunit of human ATP synthase using Profound.
Amino acid sequences of these peptides were assigned to theα-subunit of ATP synthase
as shown in Fig. 1D.
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speciﬁc ligand for the isolation of a putative HRG receptor on MOLT-4
cells. Membrane fractions of MOLT-4 cells were prepared by repeated
freeze-thawingandsolubilizedwith2%TritonX-100 inPBS.Theextracts
were applied to an Arg23-Lys66 Celluloﬁne column and binding
proteins were eluted stepwisely with 0.5 M NaCl, 1 M NaCl and 2 M
NaCl in phosphate buffer containing 1% Triton X-100. The tightly bound
proteins were ﬁnally eluted with 20 mM Gly–HCl buffer, pH 2.5,
containing 1% Triton X-100. Proteins in each fractionwere examined by
SDS-PAGE. As shown in Fig. 1A, numerous proteins were present in the
0.5MNaCl and pH 2.5 eluates, whereas a few proteinswere detected in
the 1 M and 2 M NaCl eluates. To detect cell surface proteins in each
eluate, surface proteins onMOLT-4 cells were labeled by Sulfo-NHS-LC-
biotin [15], and the Arg23-Lys66-binding proteins were puriﬁed in the
samemanner. In this case, the proteinpattern in each eluatewas similar
to that obtained from untreated MOLT-4 cells (data not shown). After
blotting to the PVDF membrane, the surface proteins were speciﬁcally
detected by streptavidin and biotinyl-horseradish peroxidase. A 55 kDa
Fig. 2. Localization of the α- and β-subunits of ATP synthase on the surface of MOLT-4 cells. MOLT-4 cells were ﬁxed, and α-subunit (A, B) and β-subunit (C, D) of ATP synthase on
the unpermeabilized (A, C) or the permeabilized cells (B, D) were detected by the immunoﬂuorescent staining method as described in Materials and methods. Scale bar
represents 10 μm. Cells were incubated with the antibody against α- (E) or β- (F) subunit of ATP synthase and analyzed by FACS with PE conjugated anti-mouse IgG secondary
antibody. Gray ﬁlling: isotype control antibody, solid line: each antibody. The suppression of anti-β-subunit antibody binding by preincubation with HRG was also analyzed (G).
Gray ﬁlling: isotype control antibody (IgG1), thick line: anti-β-subunit antibody with 0.1% BSA-preincubated cells, thin line: anti-β-subunit antibody with preincubated cells in
0.1% BSA containing 10 μg/ml HRG.
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band I). The result suggests that the 55 kDa protein is a primary
candidate for the HRG-binding protein on the surface of MOLT-4 cells.
3.2. The 55 kDa protein was identiﬁed as the α-subunit of ATP synthase
Sincewe could conﬁrm that the 55 kDa protein in the pH 2.5 eluate
(Fig. 1A, lane 4, band I) was a major Arg23-Lys66-binding protein onMOLT-4 cell surface, the 55 kDa protein band on SDS-PAGE (Fig. 1A,
lane 4, band I) was analyzed by the peptide mass ﬁnger printing
method (Fig. 1C). The observed masses of 8 peptides matched well
with the calculated masses of tryptic peptides derived from the α-
subunit of human F1FO-ATP synthase (Table 1, Fig. 1D). Thus, the
55 kDa protein was identiﬁed as the α-subunit of ATP synthase. In
order to conﬁrm that the 55 kDa band is really the α-subunit of ATP
synthase, the pH 2.5 eluate was analyzed by immunoblot analysis. In
Fig. 3. Interaction analysis of mitochondrial ATP synthase and several plasma proteins with immobilized HRG using an IAsys resonant mirror biosensor. (A) F1FO-ATP synthase
(82.1 nM), antithrombin (3.69 μM), fetuin-A (3.26 μM) or BSA (2.53 μM) was added to an HRG-immobilized cuvette, and binding was monitored for 5 min. (B) For determination of
the dissociation constant (Kd) between F1FO-ATP synthase and HRG, F1FO-ATP synthase at 82.1, 41.1, 20.5, 10.3, 5.13, 2.57, 1.28 or 0.64 nM was added to an HRG-immobilized cuvette,
and binding wasmonitored for 5min. Partial suppression of F1FO-ATP synthase (33 nM) binding to the immobilized Arg23-Lys66 glycopeptide by HRG at 0.28 or 1.4 μM(C) and by the
Arg23-Lys66 glycopeptide at 0.48, 0.98 or 2.4 μM (D) were monitored.
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Arg23-Lys66-Celluloﬁne, since some proteins non-speciﬁcally bound
to Celluloﬁne complicated the identiﬁcation. A Tris-conjugated
Sepharose column was placed as a pre-column to reduce non-
speciﬁcally-bound proteins. As shown in Fig. 1E, the α-subunit
(56 kDa) and β-subunit (52 kDa) of mitochondrial ATP synthase
were closely migrated on SDS-PAGE (Fig. 1E, lane 3). By the
immunodetection, theα-subunit of ATP synthasewas readily detected
in the pH 2.5 eluate (Fig. 1F, lane 2). Moreover, the β-subunit of ATP
synthase was also detected in the same pH 2.5 eluate (Fig. 1G, lane 2).
These results strongly suggest that the Arg23-Lys66-binding protein
on the surface of MOLT-4 cells is the cell surface-type ATP synthase.
3.3. α- and β-subunits of ATP synthase are present on the surface of
MOLT-4 cells
F1FO-ATP synthase is generally known to catalyze the mitochon-
drial ATP synthesis from ADP and orthophosphate using a proton
gradient and associated membrane potential. However, the presence
of the α- and β-subunits of ATP synthase on the plasma membrane of
human umbilical vein endothelial cell and several tumor cell lines has
been reported recently [27–29]. Therefore, we tried to conﬁrm the
presence of the α- and β-subunits of ATP synthase on the surface of
MOLT-4 cells by an immunoﬂuorescence staining method. In this
regard, both the α- and β-subunits of ATP synthase could be detected
on the surface of unpermeabilized MOLT-4 cells as punctuate “hot
spots” (Fig. 2A, C), whereas more heavily stained spots were detected
inside the permeabilized cells (Fig. 2B, D). These results suggest the
possibility that the α- and β-subunits form the ATP synthase complex
on the surface of MOLT-4 cells, and that this ATP synthase complex
interacts with HRG. Further conﬁrmation was performed by FACS
analysis. In this case, only the β-subunit of ATP synthase could be
detected on the cell surface (Fig. 2F), whereas the α-subunit of ATP
synthase could not be detected (Fig. 2E). To conﬁrm the speciﬁcbinding of HRG to the cell surface ATP synthase, effect of HRG on the
binding of anti-β-subunit antibody was analyzed. Although preincu-
bation with 0.1% BSA suppressed the binding of anti-β-subunit
antibody, addition of HRG enhanced the suppression further (Fig. 2G).
3.4. HRG binds to mitochondrial ATP synthase with high afﬁnity
To analyze the interaction of HRG with ATP synthase in detail, we
investigated the binding speciﬁcity and the binding constant for the
interaction of HRG and F1FO-ATP synthase using an IAsys resonant
mirror biosensor. Since the cell surface ATP synthase (ecto-ATP
synthase) has not been puriﬁed yet, F1FO-ATP synthase puriﬁed from
bovine heart mitochondria was used. First, we checked the binding
speciﬁcity. Bovine mitochondrial F1FO-ATP synthase interacted with
immobilized HRG, whereas several plasma proteins such as antith-
rombin, fetuin-A and BSA did not substantially interact with
immobilized HRG (Fig. 3A). The binding was concentration dependent
and the apparent dissociation constant (Kd) for F1FO-ATP synthase
binding to immobilized HRG was calculated to be 66 nM (Fig. 3B). We
also observed the interaction between the immobilized Arg23-Lys66
glycopeptide and F1FO-ATP synthase and this interaction was
effectively suppressed by competition with free HRG or free Arg23-
Lys66 glycopeptide (Fig. 3C, D).
3.5. Morphological changes of MOLT-4 cells by Con A and HRG treatment
are blocked by anti-ATP synthase β-subunit antibody
Although we conﬁrmed that HRG could interact with ecto-ATP
synthase, this ﬁnding does not prove that this association is relevant
to the morphological changes induced in MOLT-4 cells by HRG in
concert with Con A. It has been reported that anti-α- and β-subunits
of ATP synthase antibodies blocked the caspase activation in
endothelial cells triggered by binding of kringle 1–5 of plasminogen
to the ecto-ATP synthase [30]. Therefore, we investigated whether
Fig. 4. The inhibitory effect of anti-β-subunit antibody for mitochondrial ATP synthase on the morphological changes of MOLT-4 cells. MOLT-4 cells were preincubated with anti-α-
subunit of ATP synthase antibody (anti-α Ab; 280 nM), anti-β-subunit of ATP synthase antibody (anti-β Ab; 140 or 280 nM) or isotype control antibody IgG1 or IgG2b (280 nM) for
1 h at 37 °C, and then Con A (400 nM) and HRG (30 nM) were added. After 6 h, the number of adhered cells was counted under a light microscope.
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change of MOLT-4 cells triggered by Con A and HRG treatment.
UntreatedMOLT-4 cells poorly adhered to a culture dish and theywere
observed as round cells by light microscopy. In contrast, after the
treatment with Con A alone for 6 h, a fraction (about 35%) of the cells
became adherent with typical changes in morphology. HRG signiﬁ-
cantly enhanced this change in concert with Con A, and nearly 80% of
the cells changed their shapes (Fig. 4). We assessed the effects of
preincubation of MOLT-4 cells with anti-α- or β-subunit antibody on
the morphological change caused by the addition of Con A and HRG.
Interestingly, only anti-β-subunit antibody blocked themorphological
changes in a dose-dependent manner, and the anti-α-subunit anti-
body or the isotype control antibody IgG1did not (Fig. 4).
4. Discussion
In 1989, Saigo et al. [7] reported that HRG bound to peripheral T-
lymphocytes and that the binding was not inhibited by heparin. These
authors also identiﬁed a speciﬁc 56 kDa HRG receptor on T-cells, but
this receptor was not characterized further. Similarly, Lamb-Wharton
and Morgan [23] showed the morphological change-enhancing
activity of HRG on MOLT-3 cells as if the speciﬁc receptor existed on
the cell surface. Later, Olsen et al. [31] reported that HRG bound to cell
surface glycosaminoglycan on MOLT-4 cells in a zinc-dependent
manner. Jones et al. [20] further reported that HRG bound to CHO cell
surface heparan sulfate via its cystatin-like 1 and 2 domains, and that
the binding was greatly potentiated by 20 μM zinc. In our previous
work (Ohta et al., in preparation), we showed that HRG induced
morphological changes and adhesion to culture dishes of MOLT-4 cells
stimulated by Con A, and that this effect of HRG was not inﬂuenced by
50 μg/ml heparin, providing evidence for the presence of an HRG
receptor distinct from cell surface glycosaminoglycan. In the present
study, we identiﬁed the ATP synthase as an HRG-binding protein on
the plasmamembrane of MOLT-4 cells, and conﬁrmed its involvement
in the morphological changes of MOLT-4 cells triggered by HRG/Con A
treatment.
In our previous study, we showed that the Arg23-Lys66 glycopep-
tide, as well as the native HRG, in concert with Con A induced
morphological changes and adhesion of MOLT-4 cells to culture
dishes. Therefore, we used this Arg23-Lys66 glycopeptide, derived
from the N-terminal cystatin-like domain 1, to isolate the HRG-
binding protein. The isolationwas performed in the absence of zinc, as
our previous results indicated that zinc had no effect on themorphological changes of MOLT-4 cells triggered by HRG/Con A
treatment. Afﬁnity isolation revealed that a 55 kDa protein in the pH
2.5 eluate was the primary candidate for the HRG-binding protein on
the surface of MOLT-4 cells (Fig. 1A, B), and this 55 kDa protein was
subsequently identiﬁed as the α-subunit of ATP synthase by the
peptide mass ﬁnger printing method. This identiﬁcation was further
conﬁrmed by immunoblot analyses (Fig. 1F). As shown in Fig. 1G, the
presence of the β-subunit in the same pH 2.5 eluate was also
conﬁrmed by western blot analysis. These results strongly indicate
that HRG interacts with ATP synthase on the cell surface of MOLT-4
cells. However, identiﬁcation of the β-subunit and other small
subunits of ATP synthase was not successful by the peptide mass
ﬁnger printing method. Since ATP synthase is known to consist of
α3β3γδɛ subunits, together with several membranous subunits,
isolation and identiﬁcation of the α-subunit of ATP synthase as a
binding protein might be incidental and the directly interacting
subunit or protein might be the other component(s) of the complex.
As shown in Fig. 1A, besides a 55 kDa band, several other protein
bands were observed in pH2.5 eluate. Major bands were analyzed by
the peptide mass ﬁnger printing method and those bands numbered
II, III, and VI could be successfully identiﬁed as the elongation factor
Tu, core protein 2 of mitochondrial cytochrome c reductase, and ADP/
ATP translocase, respectively. Bands IV and V could not be identiﬁed.
Since these proteins were known as the mitochondrial or cytosolic
proteins and the extents of labeling with biotin were low, we
concluded that these proteins were not located on the cell surface
and excluded from the candidates for the cell surface HRG-binding
protein.
Since ATP synthase is well known as a mitochondrial enzyme, the
presence of this enzyme on the cell surface was somewhat surprising.
Therefore, we conﬁrmed the presence of both α- and β-subunits on
the surface of intact MOLT-4 cells by immunoﬂuorescence staining
and FACS analysis (Fig. 2). Because both α- and β-subunits could be
detected as punctuate “hot spots” on the surface of unpermeabilized
cells, they are not evenly distributed on the surface and may be
present in lipid rafts as suggested by others [32,33]. Permeabilization
process enriched the staining very much, reﬂecting the detection of
intracellular mitochondrial enzymes. However, the ﬁxation procedure
itself may cause the deterioration of the cellular structure, and
therefore, we further conﬁrmed the presence of ATP synthase on the
cell surface by FACS analysis. As shown in Fig. 2F, the β-subunit is
deﬁnitely located on the cell surface, while the presence of α-subunit
on the cell surface could not be proved (Fig. 2E). In this regard, it is
1106 T. Ohta et al. / Biochimica et Biophysica Acta 1788 (2009) 1099–1107possible that the reactivity of anti-α-subunit of ATP synthase antibody
is too weak to react to α-subunit with native folding. The anti-α-
subunit antibody can react well with the denatured α-subunit as
proved by western blot (Fig. 1F). Prior to immunostaining, the cells
were ﬁrst ﬁxed with paraformaldehyde, which might have caused the
denaturation of component proteins and enhanced the reactivity
against the anti-α-subunit antibody. Another possibility for the failure
of detection of α-subunit by FACS analysis is that the α-subunit was
masked by some other component(s) on the cell surface and the anti-
α-subunit antibody was not able to react with the target protein.
In general, F1FO-ATP synthase is known to localize on the
mitochondrial inner membrane and catalyze ATP synthesis. However,
recent studies have shown that F1FO-ATP synthase is also present on
the plasma membranes of endothelial cells and hepatocytes, and
functions as a receptor for several ligands such as angiostatin, p43,
vasoconstrictor coupling factor 6 and hepatic high-density lipoprotein
A-I [28,34–36]. Recently, Yonally and Capaldi [29] showed that F1FO-
ATP synthase is present on the plasma membrane of an osteosarcoma
cell line as well as several mitochondrial respiratory complexes. F1FO-
ATP synthase as an angiostatin receptor has been well characterized.
Angiostatin, a fragment of plasminogen, functions as a suppressor to
the proliferation of endothelial cells by inhibiting ATP synthesis by the
cell surface-type ATP synthase, and inhibits the ATP hydrolyzing
activity of F1 complex separated from mitochondrial F1FO-ATP
synthase in vitro [28]. In addition, Fabre et al. [37] have recently
illustrated a signaling model composed of ecto-ATP synthase,
extracellular ADP and P2Y13 receptor on hepatocytes, in which ecto-
ATP synthasewas suggested to be involved in the purinergic signaling.
The relationship between ATPase or ATP synthesis activity and the
morphological change is not clear at present. We could not detect any
effect of HRG on the ATP hydrolyzing activity of mitochondrial F1FO-
ATP synthase. We could not observe any effects of supplemental ATP
or ADP on the morphological change of MOLT-4 cells (data not
shown). However, as shown in Fig. 3, HRG interacted with F1FO-ATP
synthase speciﬁcally and with high afﬁnity. The Kd for this interaction
was 66 nM. This Kd value is about 3 times higher than the value
(19.2 nM) previously determined for high afﬁnity binding of HRG to T-
cells [7]. However, the difference in afﬁnitymay be due to the different
origin of each enzyme, bovine mitochondria versus human T-cell
surface. In IAsys analysis, mitochondrial ATP synthase was easily
detached from immobilized HRG by 0.5 M NaCl, while the isolated
proteins by afﬁnity puriﬁcation could be dissociated only with the
solution of pH 2.5. This is suggestive that the isolated putative HRG
receptor is not the same entity as the mitochondrial ATP synthase,
even though it contains α- and β-subunits as its components.
To reveal involvement of ecto-ATP synthase to the morphological
changes of MOLT-4 cells, we investigated whether the antibody
against α- or β-subunit could interfere with the morphological
changes of MOLT-4 cells induced by HRG/Con A treatment. As shown
in Fig. 4, the anti-α-subunit antibody had no effect, whereas the anti-
β-subunit antibody inhibited the morphological changes of MOLT-4
cells. This may be merely due to the poor reactivity of anti-α-subunit
antibody to the cell as indicated by FACS analysis. Thereby it is possible
that the anti-β-subunit antibody blocks the interaction between ecto-
ATP synthase and HRG, resulting in the inhibition of morphological
changes of MOLT-4 cells induced by HRG/Con A treatment. The fact
that anti-β-subunit antibody can block HRG-induced morphological
change demonstrates that ecto-ATP synthase on the cell surface is
involved in triggering the signaling pathway inducing the cytoskeletal
rearrangement events. The morphological change is not induced by
HRG alone and needs an auxiliary effect of an external lectin that
recognizes the carbohydrate chain of HRG. Interaction of the
carbohydrate moiety of HRG and Con A is essential to this cellular
morphological change because addition of methylmannopyranoside
[23] and removal of the carbohydrate chain from the Arg23-Lys66
glycopeptide completely inhibited and lost, respectively, the ability toinduce the morphological change. Therefore, the multiprotein com-
plex consisted of ecto-ATP synthase, HRG, lectin and other target
molecule(s) may be responsible for the initiation of signaling. Or
lectin may merely polymerize the ecto-ATP synthase–HRG complexes
to initiate the cellular event. The requirement of external lectin may
make this morphological change model quite unphysiological. But in
other words, if the cross-linking molecules between HRGs that take
place of Con A can be identiﬁed and shown to cause the cell adhesion
and morphological change, then this phenomenon may become an
attractive model for the metastasis, since ecto-ATP synthase are
reported to be expressed in many tumor cell lines [27,29,38] and HRG
is abundant in plasma and has high potentials to interact with various
protein partners.
In summary, we have identiﬁed the cell surface ATP synthase as a
novel HRG-binding protein on MOLT-4 cells, and discussed the
possible mechanisms involved in inducing the morphological change
of MOLT-4 cells by HRG in concert with Con A. We believe that the
result of this work provides the novel roles of HRG and HRG-binding
protein in physiological systems.
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